NCT01030536 2018-04-09
Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)
MedImmune LLC
Phase 1/2 Completed
Clinical Trials
5 trialsNCT00659425 2017-10-02
CAT-8015 in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
MedImmune LLC
Phase 1 Completed
NCT00587457 2017-07-06
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia
MedImmune LLC
Phase 1 Terminated
NCT02338050 2015-09-16
Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic Leukemia and Minimal Residual Disease Prior to Allogeneic Hematopoietic Stem Cell Transplantation
Center for International Blood and Marrow Transplant Research
Phase 2 Terminated
NCT00587015 2011-11-22
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)
MedImmune LLC
Phase 1 Terminated